Assertio Holdings (ASRT) Cash from Financing Activities (2019 - 2026)
Assertio Holdings' (ASRT) quarterly Cash from Financing Activities came in at -$189000.0 in Q1 2026, down 70.27% year-on-year from -$635727.3 in Q1 2025, and down 9350.0% quarter-over-quarter from -$2000.0 in Q4 2025.
Assertio Holdings (ASRT) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed Cash from Financing Activities across 8 years of filings, most recently posting -$189000.0 for Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$189000.0, down 70.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$267000.0 (down 4.71% YoY), and the FY2025 annual result was -$189000.0, up 46.0% from the prior year.
- Cash from Financing Activities came in at -$189000.0 for Q1 2026 at Assertio Holdings, down from -$2000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $2.9 million in Q3 2022 to a low of -$19.0 million in Q1 2023.
- The 5-year median for Cash from Financing Activities is -$111000.0 (2025), against an average of -$3.1 million.
- Across the five-year window, Cash from Financing Activities jumped 911.24% in 2022 and slumped 1017.17% in 2023, its largest moves.
- Assertio Holdings' Cash from Financing Activities stood at -$798000.0 in 2022, then plunged by 1017.17% to -$8.9 million in 2023, then soared by 99.34% to -$59000.0 in 2024, then jumped by 96.61% to -$2000.0 in 2025, then tumbled by 9350.0% to -$189000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$189000.0 (Q1 2026), -$2000.0 (Q4 2025), and -$7000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn | -189,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -189,000.00 |
| Mar 31, 2026 | -189,000.00 |
| Dec 31, 2025 | -2,000.00 |
| Dec 31, 2025 | -2,000.00 |
| Sep 30, 2025 | -7,000.00 |
| Sep 30, 2025 | -7,000.00 |
| Jun 30, 2025 | -69,000.00 |
| Jun 30, 2025 | -69,000.00 |
| Mar 31, 2025 | -111,000.00 |
| Mar 31, 2025 | -111,000.00 |
| Dec 31, 2024 | -59,000.00 |
| Dec 31, 2024 | -59,000.00 |
| Sep 30, 2024 | -10,000.00 |
| Sep 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -75,000.00 |
| Jun 30, 2024 | -75,000.00 |
| Mar 31, 2024 | -206,000.00 |
| Mar 31, 2024 | -206,000.00 |
| Dec 31, 2023 | -8.92 Mn |
| Dec 31, 2023 | -8.92 Mn |